Professionals 242 Users Online

Patient-controlled Analgesic Pumps Market

Market Study on Patient-controlled Analgesic Pumps: Surge in cancer cases globally to be pivotal for the market growth

Global Patient-controlled Analgesic Pumps Market by Electronic and Mechanical Type - Electrically Patient-Controlled Analgesia Pumps consists over 57% of shares in Patient-controlled Analgesic Pumps Market

Patient-controlled Analgesic Pumps Market Outlook (2023 to 2033)

Newly-released Patient-controlled Analgesic Pumps Market analysis report by Persistence Market Research reveals that global sales of the Patient-controlled Analgesic Pumps Market in 2022 were held at US$ 337 Mn. With a CAGR of 7.1%, the market is projected to reach a valuation of US$ 712 Million by 2033. Electronic Patient-controlled Analgesic Pumps is expected to be the highest revenue-generating segment, projected to grow at a CAGR of over 7.1% from 2023 to 2033.



Global Patient-controlled Analgesic Pumps Market (2023)

US$ 360 Million

Global Patient-controlled Analgesic Pumps Market (2033)

US$ 712 Million

Global Patient-controlled Analgesic Pumps Market CAGR (2023 to 2033)


U.S. Patient-controlled Analgesic Pumps Market CAGR (2023 to 2033)


Key Companies Profiled

  • Smiths Group plc.
  • Fresenius Kabi Group
  • Hospira
  • Micrel Medical Devices,
  • Ace Medical Co. Ltd.
  • Terumo Corporation
  • B.Braun Melsungen AG
  • Baxter International
  • Becton Dickinson and Company
  • ICU Medical
Sample Report

FREE Report Sample is Available

In-depth report coverage is now just a few seconds away

Download PDF Get FREE Report Sample

Revenue of Patient-controlled Analgesic Pumps Market from 2018 to 2022 Compared to Demand Outlook for 2023 to 2033

As per the Patient-controlled Analgesic Pumps Market research by Persistence Market Research - a market research and competitive intelligence provider, historically, from 2018 to 2022, the market value of the Patient-controlled Analgesic Pumps Market increased at around 6.9% CAGR.

Along with a growth in the prevalence of chronic pain illnesses such as rheumatoid arthritis, cancer, and fibromyalgia, the market is experiencing an increase in new product introductions. Globally, persistent non-malignant pain is prevalent among cancer patients, according to a study paper released in January 2020 by the MD Anderson Cancer Center.

Effective pain treatment is critical for cancer patients. Furthermore, the increased demand is also due to recent technological advancements that have increased patient satisfaction via ease of use, as well as increased acceptability among patients who are unable to take oral medications due to medical issues.

Custom Report Cover

Make This Report Your Own

Take Advantage of Intelligence Tailored to your Business Objective

> Get a Customized Version

What Factors are Propelling Patient-controlled Analgesic Pumps Demand?

The World Health Organization reported that diseases related to bodily pain have increased worldwide, with afflicted individuals increasing in number, which would result in favorable growth for the overall industry.

According to the Centers for Disease Control and Prevention, currently, over 20% of people in the United States suffer from chronic pain. Furthermore, the incidence of chronic pain is predicted to rise in the forthcoming years as diabetes as well as cancer survival rates rise. Patient-controlled analgesia pumps are becoming more popular as the incidence of chronic pain persists, necessitating the use of analgesic pumps for immediate pain treatment.

Expansion in the number of cancer diagnoses is likely to increase the growth of this market. The National Cancer Institute anticipates that more than 1.8 Million newly diagnosed cases of cancer will occur in the U.S. in 2020.

In contrast to relying on numerous intravenous pain medications, patient-controlled analgesia pumps, as opposed to several routine injections, are typically used throughout post-operative repair as they offer less intrusive, constant pain relief. Besides, the PCA pump makes it possible for patients to be able to autonomously administer large dosages of drugs right into the vein with a mere touch of a button on the device's control panel. It also aids in the treatment of pain after surgery, allowing for a faster recovery.

These pumps have the effect of stopping or eliminating the need for intramuscular injections. It will not bring the same side consequences as other substances. Apart from this, it also has a good impact on patient comfort, analgesic outcomes, and the incidence of pulmonary disorders. A number of benefits offered by PCA pumps have led to their fast growth within the medical field. As a result, patient satisfaction, pain management, and postoperative complications have improved, leading to the growth of the device market.

Patients for home pain management utilize patient-controlled analgesia pumps in a number of different configurations, which is useful during an epidemiological crisis when hospital visits are limited. CME Medical's TPCA Patient Controlled Analgesia Syringe Pump, for example, can be used both in the hospital and at home conditions to accommodate the patient's needs and preferences. These miniature and portable pumps are versatile for both ambulatory and bedside use, and their increasing demand in home-based patient care will encourage the growth of the PCA pump market.

Patient-controlled pain medication pumps, such as those used to treat postoperative pain are available in several shapes and can be useful to people with many different health conditions. Patient-administered analgesic pumps, such as patient-controlled infusion devices (PCID) and non-invasive versions of patient-controlled analgesia (PCA), often offer more options for managing pain.

PCA and other technological advances will continue to provide justification for PCA treatments, such as variable-rate infusions triggered based on patient pain for a better pain management system and heightened patient monitoring.

Market Research Methodology

Market Research Methodology

-Perfect through Years of Diligence

Check Research Methodology

How the Emergence of Technology Pulled the Growth Trigger in Patient-controlled Analgesic Pumps Market?

Pain may be reduced and patient preference can be increased because of incorporating the most recent technology into PCA pumps. As a result, the market growth will be accelerated. Patient self-administration of bolus analgesic medicine is made feasible by Acromed Chroma infusion pumps, which are equipped with pain management technology. In addition to assisting patients in regulating their pain and enabling them to feel comfortable, this reduces the need for on-site assistance from hospital personnel and volunteers.

Sales Team

Sales Team
Client Partner

Let's Connect

Connect me to identify winning opportunities

Ask An Expert
I'm Available

Region-wise Analysis

Which Region is projected to Offer Significant Opportunity for the Patient-controlled Analgesic Pumps Market?

Due to a rise in the number of cancer cases, accidents, diabetes, and other disorders needing pain management in the area, North America is expected to account for a significant share of the global PCA pumps market in the forthcoming years. Apart from this, a large senior population owing to a huge baby boomer population in the United States necessitates the development of effective analgesics.

According to the International Diabetes Federation, more than 48 million people in North America will have diabetes in 2019, with more than half of those patients being over the age of 65. Increased health awareness among the public about the importance of pain management is also expected to help to the market growth in the region over the projected period.

Country-wise Analysis

U.S. Patient-controlled Analgesic Pumps Market Analysis

During the forecast period, the market in Asia Pacific is expected to account for a significant proportion of the market revenue during the forecast period. China is estimated to account for nearly a quarter of all cancer cases identified worldwide by 2020.

The increasing prevalence of chronic illnesses and better healthcare, as well as the expanding usage of homecare devices in developing countries, will all contribute to the growth of this market. An aging population, people’s enhanced knowledge of pain management, and improved healthcare services and infrastructure will contribute to the market growth in the country.

U.K. Patient-controlled Analgesic Pumps Market Analysis

The market in the U.K. is expected to reach a valuation of US$ 30.5 Million by 2033. Growing with a CAGR of 7% during the forecast period, the market in the country is projected to garner an absolute dollar opportunity of US$ 15 Million.

Japan Patient-controlled Analgesic Pumps Market Analysis

In Japan, the market is expected to grow at a CAGR of 7.7% from 2023 to 2033, reaching US$ 29.5 Million by 2033. The market in the country is expected to gross an absolute dollar opportunity of US$ 15.5 Million during the forecast period.

Category-wise Insights

Why Oncology is projected to Witness Significant Growth among Patient-controlled Analgesic Pumps Application?

Oncology is expected to account for the largest revenue share of the market throughout the projected period. In part, this dominance may be explained by the increasing usage of this medication in the therapy of persistent cancer pain. Physicians use very powerful opioid medications, such as hydromorphone, morphine, and fentanyl, which are supplied by PCA infusions, to relieve the terrible anguish of their patients' conditions.

The rising usage of PCA pumps in such scenarios to improve the overall quality of life is expected to propel the segment's growth in the forthcoming years. Additionally, a rise in the use of these devices to avoid the dose dumping of pain drugs is predicted to contribute to the growth of the overall market revenue during the forecast period.

Which type of Patient-controlled Analgesic Pumps is expected to Score Significant Growth in the Coming Years?

Patient-controlled analgesic pumps with a share of over 57% consist of segments of electrically patient-controlled analgesia pumps. To successfully regulate the flow rate in a particular brand of patient-controlled analgesia pump, a system with a high-performance microprocessor and control circuits is essential.

Since electronic pain medication pumps are effective and safe for Patient-controlled Epidural Analgesia (PCEA) during birth as well as, post-delivery, there is an increase in demand for these pumps. Research has demonstrated that electronic PCA pumps are suitable for a broad group of patients because they can be tailored to meet the requirements of each patient.

With electronic PCA pumps, it is possible that a number of PCA treatment errors can occur. Possible issues affecting dosing may occur, including human and equipment errors. This means that growth may be stunted during the analysis stage.

Mechanical PCA pumps are the second-largest category of medical equipment and have the highest potential for growth due to their benefits. Mechanical patient-controlled analgesia pumps are good options for medical professionals and patients alike.

Mechanical PCA pumps are compact, inexpensive, maintain accuracy, do not require coding mistakes, and are easy to transport. The mechanical analgesic pumps are more successful than their hydraulic counterparts with fewer failures and higher satisfaction of patients.

Competitive Analysis

With a number of prominent producers, the PCA pump industry is relatively competitive. The sector is now controlled by a few rivals in terms of market share. Among the market leaders are Smiths Group Plc, Becton, Dickinson and Company, Fresenius SE & Co. KGaA, B. Braun Melsungen AG, and Baxter International Inc.

  • In April 2022, Smiths Medical entered into a partnership with Bainbridge Health. The partnership is focused on providing pharmacy and safety leaders with visibility into trends in intravenous medication safety and utilization.
  • In January 2022, BD entered into a definitive agreement to acquire Parata Systems in a deal size of US$ 1.5 Billion.

Similarly, the team at Persistence Market Research has been tracking recent developments of the companies operating in the Patient-controlled Analgesic Pumps Market, which are featured in the full report.

Market Segments Covered in Patient-controlled Analgesic Pumps Market Analysis

By End Use

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Home Care Settings

By Type

  • Electronic
  • Mechanical

By Application

  • Diabetes
  • Oncology
  • Gastroenterology
  • Hematology
  • Other Applications

By Region

  • North America
  • Latin America
  • Europe
  • APAC
  • MEA

- Companies Covered in This Report -

  • Smiths Group plc
  • Fresenius SE & Co KGaA
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Becton, Dickinson and Company
  • ICU Medical, Inc.
  • ACE Medical
  • Terumo Corporation
  • Pfizer Inc

- Frequently Asked Questions -

The global Patient-controlled Analgesic Pumps Market is worth more than US$ 337.1 Mn at present.

The market value is projected to increase at a CAGR of around 7.1% from 2023 to 2033.

The market value increased at a CAGR of around 6.9% during 2018 – 2022.

The market for Patient-controlled Analgesic Pumps Market in China is projected to expand at a CAGR of around 9.4% from 2023 to 2033.

While the market in South Korea is expected to grow at nearly 7.2%, the market in Japan is projected to register a CAGR of nearly 7.7% during 2023 - 2033.

This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy
Google translate